GYRE_OUT_1 [2025-04-02 11:46:54 -0400] 3390 Bytes | 912 tokens | Cum: 912 tkns (11.40% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 11:46:53 AM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on Gyre Therapeutics (GYRE), moving from 6.41 to 7.37. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Gyre Therapeutics (GYRE)
IPO: 2023-10-31 (1 Year Ago)
Market Cap: $600,055,753
Shares Outstanding: 85,820,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Here's the first list of news for Gyre Therapeutics:

C1 - Mar-31-25 07:00AM - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
C2 - Mar-27-25 07:00AM - Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
C3 - Mar-21-25 09:14AM - Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
C4 - Mar-17-25 04:15PM - Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
C5 - Jan-06-25 07:00AM - Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
C6 - Nov-13-24 06:00AM - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
C7 - Oct-22-24 04:05PM - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
C8 - Oct-01-24 04:05PM - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Prior AI Reports for GYRE:
1. 2025-03-19 – Score: 45 – Target: 10.5000 – Highs: 10.3700 / 10.6000 / 10.13
solid-sales-growth-amidst-short-term-performance-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Gyre Therapeutics (GYRE)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GYRE_OUT_3 [2025-04-02 11:47:04 -0400] 1099 Bytes | 339 tokens | Cum: 1253 tkns (15.66% of 8k)
==========================================================================

Showing C4 (chunk 1 of 11): C4:
**Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update**
Date: Mar-17-25 04:15PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3044101/0/en/Gyre-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

March 17, 2025 16:15 ET| Source:Gyre Therapeutics Inc.Gyre Therapeutics Inc.

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025

Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025

Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025

Full year 2025totalrevenue guidance of $118 to $128 million

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre T

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_5 [2025-04-02 11:47:05 -0400] 969 Bytes | 293 tokens | Cum: 1692 tkns (21.15% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T14:13:46Z - Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Mo...
A2 - 2025-04-01T19:31:15Z - Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - Time to Sell?...
A3 - 2025-03-31T16:26:06Z - GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges By Investing.com...
A4 - 2025-03-31T11:28:44Z - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Onco...
A5 - 2025-03-31T11:28:41Z - Chicago Atlantic BDC, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GYRE_OUT_7 [2025-04-02 11:47:12 -0400] 1098 Bytes | 304 tokens | Cum: 1998 tkns (24.98% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Arcellx (NASDAQ:ACLX), Allegiant Travel (NASDAQ:ALGT)**Date: 2025-04-02Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44607975/cognyte-software-posts-upbeat-results-joins-angiodynamics-allegiant-travel-and-other-big-stocks-moving-higher-on-wednesdayU.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.

Shares of Cognyte Software Ltd. CGNT rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.

Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.

C

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_9 [2025-04-02 11:47:22 -0400] 1098 Bytes | 339 tokens | Cum: 2420 tkns (30.25% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): ognyte Software shares jumped 22.1% to $10.04 on Wednesday.

Here are some other big stocks recording gains in today's session.

AngioDynamics, Inc. ANGO shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates. Rocket Companies, Inc. RKT gained 13.1% to $14.26. Cytokinetics, Incorporated CYTK shares rose 12% to $41.99. Redfin Corporation RDFN shares surged 11.7% to $10.69. CoreWeave, Inc. CRWV gained 10.1% to $57.90. Gyre Therapeutics, Inc. GYRE rose 9.8% to $7.04. Mr. Cooper Group Inc. COOP surged 9.5% to $136.97. Sana Biotechnology, Inc. SANA gained 8.3% to $1.6250. Allegiant Travel Company ALGT rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90. Studio City International Holdings Limited

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_11 [2025-04-02 11:47:23 -0400] 1018 Bytes | 299 tokens | Cum: 2924 tkns (36.55% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-18T20:05:00Z - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
B2 - 2024-05-28T20:05:00Z - Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
B3 - 2024-05-09T20:10:00Z - Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
B4 - 2024-04-11T17:33:07Z - Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2024-04-11T14:01:51Z - Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
B6 - 2024-03-26T10:00:00Z - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GYRE_OUT_13 [2025-04-02 11:47:31 -0400] 598 Bytes | 169 tokens | Cum: 3095 tkns (38.69% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/09/2879221/0/en/Gyre-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.htmlGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_15 [2025-04-02 11:47:32 -0400] 1082 Bytes | 282 tokens | Cum: 3496 tkns (43.70% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furni...

S6 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furni...

S7 - 2025-03-17 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included el...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GYRE_OUT_17 [2025-04-02 11:47:39 -0400] 1098 Bytes | 279 tokens | Cum: 3777 tkns (47.21% of 8k)
==========================================================================

Showing S4 (chunk 1 of 2): S4:
Item 2.02. Results of Operations and Financial Condition.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_19 [2025-04-02 11:47:51 -0400] 6735 Bytes | 1994 tokens | Cum: 5893 tkns (73.66% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 65,722 | Perf Month: -32.39% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 132.50K | Perf Quarter: -41.79% | Short Float: 9.38% | ROE: - |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 1.44 | Index: RUT | Short Ratio: 11.52 | ROI: 18.82% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 36.23 | Market Cap: 636.27M | Short Interest: 1.53M | Sales Surprise: 18.60% |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.15 | Shs Outstand: 86.31M | Beta: 1.89 | EPS Surprise: -100.00% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -25.06% | Shs Float: 16.27M | Sales Q/Q: - | P/E: 61.83 |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -32.45% | Inst Own: 2.07% | Sales past 5Y: 246.63% | Earnings: Mar 17 AMC |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -39.16% | Insider Own: 81.16% | Employees: 5 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: -16.15% | Insider Trans: -0.17% | Debt/Eq: 0.03 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-21
- Common Stock: 174 shares at $10 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-19
- Common Stock: 2000 shares at $10.13 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.09 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-17
- Common Stock: 2000 shares at $12.09 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 242 shares at $10.24 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-13
- Common Stock: 2000 shares at $11.8 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $12.31 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-11
- Common Stock: 2000 shares at $11.4 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $11.74 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-07
- Common Stock: 53 shares at $13.03 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 41 shares at $12.14 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 1906 shares at $10.13 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.14 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 105757000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 17898000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.47
Average Volume: 221955.13
30-Day High: 12.28
30-Day Low: 6.41

[Detailed Financials: TTM 2024]
- Total Assets: $125,406,000.0
- Total Liabilities: $27,004,000.0
- Total Equity: $98,402,000.0
- Current Assets: $64,786,000.0
- Current Liabilities: $19,516,000.0

[Income Statement: TTM 2024]
- Revenue: $105,757,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.14

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-21,423,000.0

[Detailed Financials: FY 2024]
- Total Assets: $125,406,000.0
- Total Liabilities: $27,004,000.0
- Total Equity: $98,402,000.0
- Current Assets: $64,786,000.0
- Current Liabilities: $19,516,000.0

[Income Statement: FY 2024]
- Revenue: $105,757,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.14

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-21,423,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GYRE_OUT_21 [2025-04-02 11:47:56 -0400] 676 Bytes | 167 tokens | Cum: 6329 tkns (79.11% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GYRE_IN_23 [2025-04-02 11:47:56 -0400] 126 Bytes | 29 tokens | Cum: 6426 tkns (80.33% of 8k)
==========================================================================

====================================
[2025-04-02 11:47:56] # Analysis Completed
Elapsed Time: 63.38 seconds